Related Experiment Video
Updated: Feb 5, 2026
06:01
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
15.6K
Thrombotic thrombocytopenic purpura
1Department of Medicine 1, Division of Hematology and Hemostasis, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Memo
|September 18, 2018
Summary
Thrombotic thrombocytopenic purpura (TTP) is a serious condition caused by a deficiency in ADAMTS13 enzyme activity. Recent advancements offer new, effective therapeutic strategies beyond traditional plasma exchange.
Area of Science:
- Hematology
- Internal Medicine
- Pathophysiology
Background:
- Thrombotic thrombocytopenic purpura (TTP) is a critical thrombotic microangiopathy (TMA).
- TTP involves microangiopathic hemolytic anemia, thrombocytopenia, and organ damage from microcirculation issues.
- Severe deficiency of ADAMTS13 enzyme, crucial for von Willebrand factor (VWF) cleavage, defines TTP.
Purpose of the Study:
- To review the diagnostic progress and evolving therapeutic landscape of TTP.
- To highlight the limitations of historical treatments and the emergence of novel strategies.
Main Methods:
- Review of current literature on TTP diagnosis and treatment.
- Analysis of recent therapeutic advancements including immunosuppression and targeted therapies.
Main Results:
- Significant progress in TTP diagnosis has been achieved.
- New therapeutic strategies, including immunosuppression, targeted anti-VWF/anti-complement therapy, and recombinant enzyme replacement, show promise.
- Initial treatment remains plasma exchange and supportive care.
Conclusions:
- TTP management has evolved significantly with new therapeutic options.
- Novel treatments offer improved outcomes for patients with TTP.
- Prompt diagnosis and appropriate therapy are crucial for preventing irreversible organ damage or death in TTP.
